Fig. 1: Percent change from baseline in AUA/IPSS total score-full analysis set. | Prostate Cancer and Prostatic Diseases

Fig. 1: Percent change from baseline in AUA/IPSS total score-full analysis set.

From: The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)

Fig. 1

A Percent change from baseline in AUA/IPSS total score-full analysis set. Percent change from baseline (calculated as post-baseline value – baseline value) for AUA/IPSS in the Arm-1 cohort. For the Arm-1 cohort, patients experienced a 1-month indwell duration and a 6-month post-retrieval. Error bars indicate SEM. B Percent change from baseline in AUA/IPSS total score-full analysis set. Percent change from baseline (calculated as post-baseline value – baseline value) for AUA/IPSS in Arm-2 cohort. For the Arm-2 cohort, patients experienced a 6-month indwell duration and a 6-month post-retrieval. Error bars indicate SEM. C Percent change from baseline in AUA/IPSS total score-full analysis set. Percent change from baseline (calculated as post-baseline value – baseline value) for AUA/IPSS in Arm-3 cohort. For the Arm-3 cohort, patients experienced a 12-month indwell duration. Error bars indicate SEM.

Back to article page